IS6108A - Estrógen viðtaki-ß bindlar - Google Patents

Estrógen viðtaki-ß bindlar

Info

Publication number
IS6108A
IS6108A IS6108A IS6108A IS6108A IS 6108 A IS6108 A IS 6108A IS 6108 A IS6108 A IS 6108A IS 6108 A IS6108 A IS 6108A IS 6108 A IS6108 A IS 6108A
Authority
IS
Iceland
Prior art keywords
ligands
estrogen receptor
estrogen
receptor
Prior art date
Application number
IS6108A
Other languages
English (en)
Inventor
Chistophe Barlaam Bernard
Martin Piser Timothy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6108A publication Critical patent/IS6108A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IS6108A 1999-04-16 2001-10-15 Estrógen viðtaki-ß bindlar IS6108A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12990199P 1999-04-16 1999-04-16
PCT/GB2000/001380 WO2000062765A2 (en) 1999-04-16 2000-04-11 ESTROGEN RECEPTOR-β LIGANDS

Publications (1)

Publication Number Publication Date
IS6108A true IS6108A (is) 2001-10-15

Family

ID=22442124

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6108A IS6108A (is) 1999-04-16 2001-10-15 Estrógen viðtaki-ß bindlar

Country Status (22)

Country Link
US (1) US6518301B1 (is)
EP (1) EP1173164A2 (is)
JP (1) JP2002542187A (is)
KR (1) KR20010108509A (is)
CN (1) CN1358091A (is)
AR (1) AR043085A1 (is)
AU (1) AU4128800A (is)
BG (1) BG106103A (is)
BR (1) BR0009814A (is)
CA (1) CA2370126A1 (is)
CZ (1) CZ20013714A3 (is)
EE (1) EE200100526A (is)
HU (1) HUP0200740A3 (is)
IL (1) IL145839A0 (is)
IS (1) IS6108A (is)
MX (1) MXPA01010423A (is)
NO (1) NO20015015L (is)
PL (1) PL351314A1 (is)
SK (1) SK14762001A3 (is)
TR (2) TR200201762T2 (is)
WO (1) WO2000062765A2 (is)
ZA (1) ZA200108409B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US7226945B2 (en) 2000-10-13 2007-06-05 Astrazeneca Ab Estrogen receptor-β ligands
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
WO2002046164A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US6559177B2 (en) 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
IL161325A0 (en) 2001-11-19 2004-09-27 Lilly Co Eli Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7235539B2 (en) 2002-01-23 2007-06-26 Wyeth 6-Hydroxyequilenins as estrogenic agents
AU2003212856A1 (en) * 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1545206B1 (en) 2002-07-24 2020-03-04 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US7468445B2 (en) 2002-08-07 2008-12-23 University Of Mississippi Antigiardial agents and use thereof
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
DE602004016150D1 (de) * 2003-04-21 2008-10-09 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
EP2305272A1 (en) * 2004-04-28 2011-04-06 Brigham Young University Use of equol for treating skin diseases
PE20060503A1 (es) * 2004-08-26 2006-07-20 Wyeth Corp Prodroga de benzoxazoles substituidos como agentes estrogenicos
EP1789420A2 (en) 2004-09-07 2007-05-30 Wyeth, A Corporation of the State of Delaware 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
US20060135574A1 (en) * 2004-12-17 2006-06-22 Wyeth Novel uses for estrogen beta agonists
WO2006088716A1 (en) * 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
CN101203219B (zh) * 2005-03-24 2011-06-15 诺沃根研究控股有限公司 消炎用药程式
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
US8592007B2 (en) * 2008-10-29 2013-11-26 Merck Patent Gmbh Liquid-crystal display
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN101863867B (zh) * 2009-04-14 2012-07-18 清华大学深圳研究生院 黄酮类化合物的衍生物及其制备方法与应用
WO2012147102A1 (en) * 2011-04-25 2012-11-01 Council Of Scientific & Industrial Research Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
CN103450134B (zh) * 2012-05-31 2017-12-22 中国医学科学院药物研究所 香豆素衍生物的制备及其在防治脑部重大疾病中的应用
US9718799B2 (en) * 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
EP3597187A1 (en) * 2018-07-16 2020-01-22 Centre National De La Recherche Scientifique Brag2 inhibitors and applications thereof
CN112574177B (zh) * 2020-12-21 2023-01-31 陕西师范大学 一类嘧啶衍生物及其制备抗肿瘤药物的应用
CN115322198A (zh) * 2022-06-13 2022-11-11 上海工程技术大学 基于喹诺里西啶类衍生物的药物化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954371A (is) * 1972-09-28 1974-05-27
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
JPS6048924A (ja) 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
JP3085464B2 (ja) * 1990-05-24 2000-09-11 コニカ株式会社 感熱拡散転写材料
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
JPH05112552A (ja) * 1991-10-17 1993-05-07 Tanabe Seiyaku Co Ltd ベンゾピラン誘導体及びその製法
JP3166093B2 (ja) * 1993-08-13 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH06321752A (ja) * 1993-05-07 1994-11-22 Kao Corp 美白剤
JP3522754B2 (ja) * 1993-12-16 2004-04-26 マリンクロッド・インコーポレイテッド 多価フェノール化合物類
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
GB9707013D0 (en) * 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
CA2287965C (en) * 1997-05-01 2009-10-20 Graham Edmund Kelly Treatment or prevention of menopausal symptoms and osteoporosis

Also Published As

Publication number Publication date
HUP0200740A3 (en) 2004-08-30
KR20010108509A (ko) 2001-12-07
JP2002542187A (ja) 2002-12-10
AU4128800A (en) 2000-11-02
IL145839A0 (en) 2002-07-25
HUP0200740A2 (hu) 2002-07-29
BG106103A (en) 2002-05-31
AR043085A1 (es) 2005-07-20
SK14762001A3 (sk) 2002-10-08
CZ20013714A3 (cs) 2002-08-14
CA2370126A1 (en) 2000-10-26
EP1173164A2 (en) 2002-01-23
PL351314A1 (en) 2003-04-07
NO20015015L (no) 2001-12-17
US6518301B1 (en) 2003-02-11
BR0009814A (pt) 2002-01-08
NO20015015D0 (no) 2001-10-15
TR200102992T2 (tr) 2004-12-21
MXPA01010423A (es) 2002-03-27
EE200100526A (et) 2002-12-16
CN1358091A (zh) 2002-07-10
ZA200108409B (en) 2003-03-26
WO2000062765A2 (en) 2000-10-26
TR200201762T2 (tr) 2002-10-21
WO2000062765A3 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
IS6108A (is) Estrógen viðtaki-ß bindlar
NO2019016I1 (no) dasatinib
DE60044873D1 (de) Orientierte biopolymermembrane
IS6024A (is) Ný efnasambönd
PT1202994E (pt) Novos compostos
NO20015097D0 (no) Pakning
DE69907859T2 (de) Abdichtung
IS6040A (is) Valdekoxib efnablöndur
DE60025891D1 (de) Halterlose Dichtung
FI990170A (fi) Maksunosoitus
IS6139A (is) Ný efnasambönd
DE50008637D1 (de) Dichtring
DE50005126D1 (de) Rundkamm-Garnitur
NO20031737L (no) Östrogenreseptormodulatorer
DE50015811D1 (de) Retardersystem
DE59910195D1 (de) Dichtring
ID29533A (id) Senyawa-senyawa kalsilitik
IS6141A (is) Ný efnasambönd
DE50015381D1 (de) Retardersystem
NO20003024D0 (no) Innkapsling
FI19991874A (fi) Laskutus
DE50009295D1 (de) Vernetzerfreie zubereitungen
DE29902124U1 (de) Büstenhalter
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
FI990703A0 (fi) Valikkopalvelujärjestelmä